Jupiter Asset Management’s Royalty Pharma RPRX Stock Holding History

Jupiter Asset Management’s Portfolio RPRX Stock Details RPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-2,470,706	Closed	-$89M	–	535
2025 Q2	$89M	Buy	2,470,706 +1,380,115	+127%	+$45.7M	0.74%	27
2025 Q1	$34M	Buy	1,090,591 +896,555	+462%	+$28.4M	0.33%	105
2024 Q4	$4.95M	Buy	+194,036	New	+$5.15M	0.05%	280
2023 Q4	–	Sell	-101,856	Closed	-$2.76M	–	526
2023 Q3	$2.76M	Sell	101,856 -61,344	-38%	-$1.82M	0.03%	306
2023 Q2	$5.01M	Buy	+163,200	New	+$5.53M	0.05%	282

Other funds holding RPRX

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Jupiter Asset Management's RPRX Position: Q3 2025 in Review

Jupiter Asset Management sold out of Royalty Pharma (RPRX) in Q3 2025, closing a stake of 2,470,706 shares — an estimated $89M sold.

Jupiter Asset Management first reported a position in RPRX in Q2 2023 and held it in 5 quarters. The position peaked at $89M in Q2 2025. 487 funds tracked by Wall St. Rank hold RPRX as of Q3 2025.

Jupiter Asset Management reported no remaining Royalty Pharma position as of Q3 2025 after selling out during the quarter.
Jupiter Asset Management sold 2,470,706 Royalty Pharma shares in Q3 2025, an estimated $89M.
Jupiter Asset Management first reported a position in Royalty Pharma in Q2 2023 and held it in 5 quarters.
Jupiter Asset Management's Royalty Pharma position peaked at $89M in Q2 2025.
487 funds tracked by Wall St. Rank held Royalty Pharma as of Q3 2025.

Based on Jupiter Asset Management's 13F filing for Q3 2025, filed 10 Nov 2025.